Last reviewed · How we verify
Uro-Vaxom
Uro-Vaxom, marketed by Swiss Paraplegic Research, is an established product in the urological space with a key composition patent expiring in 2028. The drug's primary strength lies in its current market presence and the protection offered by its patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Uro-Vaxom |
|---|---|
| Sponsor | Swiss Paraplegic Research, Nottwil |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Assess the Efficacy of OM-89 vs Placebo in Reducing Antibiotic Consumption Associated With the Treatment of Urinary Tract Infections in Patients With Neurogenic Bladder (PHASE3)
- The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome (PHASE4)
- Immunomodulation Therapy for Urinary Tract Infections (PHASE4)
- Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Uro-Vaxom CI brief — competitive landscape report
- Uro-Vaxom updates RSS · CI watch RSS
- Swiss Paraplegic Research, Nottwil portfolio CI